A5008897282- Health and Medical Studies
- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- Medical Practices and Rehabilitation
- Respiratory viral infections research
- Influenza Virus Research Studies
- SARS-CoV-2 and COVID-19 Research
- Pneumonia and Respiratory Infections
- Vaccine Coverage and Hesitancy
- Herpesvirus Infections and Treatments
- Respiratory Support and Mechanisms
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Poxvirus research and outbreaks
- Food Allergy and Anaphylaxis Research
- Child and Adolescent Health
- COVID-19 and healthcare impacts
- Bartonella species infections research
- Autoimmune and Inflammatory Disorders
- Urticaria and Related Conditions
- Education Methods and Technologies
- Sex and Gender in Healthcare
- Data-Driven Disease Surveillance
- Oral Health Pathology and Treatment
- Infection Control in Healthcare
- Educational Research and Analysis
Robert Koch Institute
2015-2024
Klinik und Poliklinik für Mund-, Kiefer- und Plastische Gesichtschirurgie
2021
Jena University Hospital
2021
Federal Institute for Risk Assessment
2013
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 vaccine effectiveness (IVE) estimates two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against than A(H3N2): EU-PC 53% (95% CI: 41 63) 30% −3 54) A(H3N2). For EU-H, these were 44% 30 55) 14% −32 43), respectively.
Background Non-pharmaceutical interventions (NPIs) during the COVID-19 pandemic affected respiratory syncytial virus (RSV) circulation worldwide. Aim To describe, for children aged < 5 years, 2021 and 2022/23 RSV seasons in Germany. Methods Through data 16,754 specimens from outpatient sentinel surveillance, we investigated seasonality, circulating lineages, children’s age distributions 2022/23. Available information about disease severity hospital surveillance was analysed patients with...
The first case of coronavirus SARS-CoV‑2 infection in Germany was diagnosed on 27 January 2020. To describe the pandemic course 2020, we regarded four epidemiologically different periods and used data COVID-19 cases from mandatory reporting system as well hospitalized with severe acute respiratory syndromic hospital surveillance.Period 0 covers weeks 5 to 9 where mainly sporadic younger age were observed few regional outbreaks emerged. In total, 167 mostly mild outcomes reported....
Abstract Background Respiratory syncytial virus (RSV) is the most common cause of acute lower respiratory tract infection (ALRI) in young children. ICD‐10‐based syndromic surveillance can transmit data rapidly a standardized way. Objectives We investigated use RSV‐specific ICD‐10 codes for RSV surveillance. Methods performed retrospective descriptive analysis based on existing systems ALRI primary and secondary care linked virological Germany. described epidemiology compared epidemiological...
We conducted a multicentre hospital-based test-negative case-control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 season Europe. Among 5547 SARI ≥18 years, 2963 (53%) were vaccinated influenza. Overall VE A(H1N1)pdm09 was 11% (95% CI: -23-36); 20% -4-39) A(H3N2) and 56% 22-75) B. During season, while hospitalisation B >55%, it ≤20% for A subtypes. While vaccination should be...
We conducted a multicentre hospital-based test-negative case–control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory from five countries Europe. Bivalent provided short-term additional protection compared those vaccinated > 6 months before campaign: 80% (95% CI: 50 94) for 14–89 days post-vaccination, 15% −12 35)...
Tuberculosis (TB) surveillance commonly focuses on pulmonary (PTB) where the main organ affected is lung. This might lead to underestimate extrapulmonary TB (EPTB) forms, in addition lung other sites are by TB. In Germany, notification data provide site and secondary of disease. To gain an overview all different EPTB we analysed German between 2002 2009 using information both disease describe individual forms. Further, assessed factors associated with meningitis multivariable logistic...
Information on severity of coronavirus disease (COVID-19) (transmissibility, seriousness, impact) is crucial for preparation healthcare sectors. We present a simple approach to assess creating reference cohort pneumonia patients from sentinel hospitals. First comparisons exposed higher rate COVID-19 requiring ventilation. There were more case fatalities among without comorbidities than in the cohort. Hospitals should prepare high utilisation ventilation and intensive care resources.
Syndromic surveillance of severe acute respiratory infections (SARI) is important to assess seriousness disease as recommended by WHO for influenza. In 2015 the Robert Koch Institute (RKI) started collaborate with a private hospital network develop SARI system using case-based data on ICD-10 codes. This first-time description shows its application analysis five influenza seasons. Since week 40/2015, weekly updated anonymized discharged patients overall and illness including codes primary...
Before the COVID-19 pandemic, acute respiratory infections (ARIs) in children were mainly characterised by three pathogens: syncytial viruses (RSV), influenza and rhinoviruses. The impact of pandemic measures taken Germany (especially until end 2021) on incidence ARI adolescents aged 0 to 14 years pathogens causing them has not yet been comprehensively analysed.The evaluation is based data from population-based, virological hospital-based surveillance instruments up 2022.After onset early...
Introduction The I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. Aim We aimed to measure VE against PCR-confirmed SARS-CoV-2 patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 July 2022 (Omicron-dominant period). Methods In both networks, 46 hospitals (13 countries) follow a similar test-negative case–control protocol. defined complete...
Binary file ES_Abstracts_Final_ECDC.txt matches
ABSTRACT We conducted a multicentre test‐negative case–control study covering the period from October 2023 to January 2024 among adult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. provide early estimates of effectiveness newly adapted XBB.1.5 COVID‐19 vaccines against PCR‐confirmed SARS‐CoV‐2 hospitalisation. Vaccine was 49% overall, ranging between 69% at 14–29 days and 40% 60–105 post vaccination. The conferred protection hospitalisation first...
In August 2011, the German Protection against Infection Act was amended, mandating reporting of healthcare associated infection (HAI) outbreak notifications by all workers in Germany via local public health authorities and federal states to Robert Koch Institute (RKI).To describe reported HAI-outbreaks surveillance system's structure capabilities.Information on each collected using standard paper forms notified RKI. Notifications were screened daily regularly analysed.Between November 2011...
Herpes zoster (HZ) is caused by reactivation of the varicella-zoster-virus (VZV). Childhood varicella vaccination, as recommended in Germany 2004, may reduce risk HZ vaccinated children but also virus circulation and thus booster possibility latent infected persons. In this context we analyzed age-specific trends epidemiology using data on HZ-associated outpatient consultations participating sentinel sites cases all hospitals since 2005. We two separate time periods that differed management...
We conducted a multicentre test-negative case-control study covering the period from October 2023 to January 2024 among adult patients aged ≥18 years hospitalised with severe acute respiratory infection in Europe. provide early estimates of effectiveness newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine was 48% overall, ranging between 68% at 14–29 days and 40% 60–105 post vaccination. The conferred protection hospitalisation first 3.5 months...
Respiratory diseases are major causes of disease burden and mortality throughout the world. In Germany, alongside acute respiratory infections (ARI), chronic lung - including cancer, obstructive pulmonary (COPD), asthma particular socioeconomic importance. ARI incidence rates differ significantly according to age, season year. They recorded as weekly consultation reported by selected outpatient inpatient care facilities. Between 2009 2016, highest severe infection (SARI) were among young...
Introduction Two large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021. Aim We aimed to measure VE PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients ≥ 20 years, combining data from these during Alpha (March–June)- and Delta (June–December)-dominant periods, Methods Forty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case–control...